Concepedia

Brittany Bahamón

BB

Statistics

Publications

10

Citations

472

H-Index

10

Active since

2012

Affiliations

Dana-Farber Cancer Institute(Current)

Takeda (United States)

The University of Texas MD Anderson Cancer Center

University of Colorado Denver

Millennium Engineering and Integration (United States)

Brittany Bahamón is an author at Dana-Farber Cancer Institute specializing in oncology, pharmacology, and medicine.

Publications per year

2012–2023

10

Publications

10

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

Taofeek K. Owonikoko, Huifeng Niu, Kristiaan Nackaerts et al. · Journal of Thoracic Oncology · 2019 · 147 citations · Full text

, , +16

The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma

Toni K. Choueiri, André P. Fay, Robert Gagnon et al. · Clinical Cancer Research · 2013 · 87 citations

, , +17

The Glomuvenous Malformation Protein Glomulin Binds Rbx1 and Regulates Cullin RING Ligase-Mediated Turnover of Fbw7

Adriana E. Tron, Takehiro Arai, David M. Duda et al. · Molecular Cell · 2012 · 77 citations · Full text

, , +3

NMDA receptor antagonism: escalation of aggressive behavior in alcohol-drinking mice

Emily L. Newman, Adam Chu, Brittany Bahamón et al. · Psychopharmacology · 2012 · 46 citations · Full text

, , +16

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts

X Wang, L Zhang, A. O’Neill et al. · British Journal of Cancer · 2013 · 40 citations · Full text

, , +17

1–5 of 10